Author

Jiahua Chu

Institution: Qilu Pharmaceutical Co., Ltd. (China)

Observed institution: Qilu Pharmaceutical Co., Ltd. (China)

ORCID: 0000-0001-5031-3046

Observed ORCID: 0000-0001-5031-3046

OpenAlex ID: A5017359591

IDDF2026-ABS-0266 A highly selective Kv1.3 inhibitor LUS012 demonstrates superior efficacy with near-complete histological resolution in TNBS-induced IBD model

2026 · He Sun, Hongbo Zhang, et al. · Gut

Abstract 7095: QLS1403, a novel and potent PARG inhibitor with robust anti-tumor efficacy in homologous recombination deficient cancer models

2026 · Tingting Xia, Wei Wei, et al. · Cancer Research

Works count: 2

Citation count:

H-index:

I10-index: